1-14 of 14
David Ungar
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Clinical Characteristics and Responses of Patients with Relapsed or Refractory High-Grade B-Cell Lymphoma Treated with Loncastuximab Tesirine in the Lotis-2 Clinical Trial

Juan Pablo Alderuccio, Weiyun Z. Ai, John Radford, Melhem Solh, Kirit M. Ardeshna, Matthew A. Lunning, Brian T. Hess, Pier Luigi Zinzani, Anastasios Stathis, Carmelo Carlo-Stella, Mehdi Hamadani, Brad S. Kahl, David Ungar, Turk Kilavuz, Eric Yu, Yajuan Qin, Paolo F. Caimi
Journal: Blood
Blood (2021) 138 (Supplement 1): 3575.
https://doi.org/10.1182/blood-2021-148730
Published: 2021
Journal Articles

Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma

Clinical Trials & Observations
Mehdi Hamadani, John Radford, Carmelo Carlo-Stella, Paolo F. Caimi, Erin Reid, Owen A. O’Connor, Jay M. Feingold, Kirit M. Ardeshna, William Townsend, Melhem Solh, Leonard T. Heffner, David Ungar, Luqiang Wang, Joseph Boni, Karin Havenith, Yajuan Qin, Brad S. Kahl
Journal: Blood
Blood (2021) 137 (19): 2634–2645.
https://doi.org/10.1182/blood.2020007512
Published: 2021
Includes: Supplemental data
Journal Articles

Safety and Antitumor Activity Study Evaluating Loncastuximab Tesirine and Rituximab Versus Immunochemotherapy in Diffuse Large B-Cell Lymphoma

Yuliya Linhares, MD, Mitul D Gandhi, Michael Chung, Jennifer Adeleye, David Ungar, Mehdi Hamadani, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 9–10.
https://doi.org/10.1182/blood-2020-136614
Published: 2020
Journal Articles

Symptoms, Health-Related Quality of Life, and Tolerability of Loncastuximab Tesirine in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma

Alexander I. Spira, PhD MD FACP, Lei Chen, MD PhD, Xiaolei Zhou, Ari Gnanasakthy, Luqiang Wang, David Ungar, Rafael Curiel, John A. Radford, MD FMedSci, Brad S. Kahl, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 3–4.
https://doi.org/10.1182/blood-2020-139571
Published: 2020
Journal Articles

Efficacy and Safety of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Paolo F Caimi, Weiyun Z. Ai, Juan Pablo Alderuccio, MD, Kirit M. Ardeshna, Mehdi Hamadani, MD, Brian T. Hess, MD, Brad S. Kahl, MD, John A. Radford, MD FMedSci, Melhem Solh, MD, Anastasios Stathis, MD, Pier Luigi Zinzani, MD, Jay Feingold, David Ungar, Yajuan Qin, Shui He, Carmelo Carlo-Stella, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 35–37.
https://doi.org/10.1182/blood-2020-137524
Published: 2020
Journal Articles

Safety and Anti-Tumor Activity Study of Loncastuximab Tesirine and Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma

Julien Depaus, Locke J. Bryan, MD, David Ungar, MD, Ilva Dautaj, Nina D. Wagner-Johnston, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5309.
https://doi.org/10.1182/blood-2019-126913
Published: 2019
Journal Articles

Safety and Anti-Tumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma

Craig H. Moskowitz, Mariana Bastos-Oreiro, MD PhD, David Ungar, MD, Ilva Dautaj, Matko Kalac, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2807.
https://doi.org/10.1182/blood-2019-128036
Published: 2019
Journal Articles

Interim Futility Analysis of a Phase 2 Study of Loncastuximab Tesirine, a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Carmelo Carlo-Stella, MD, Pier Luigi Luigi Zinzani, MD, Brad S. Kahl, MD, Paolo F Caimi, MD, Melhem Solh, MD, William Townsend, MRCP,MDFRCPath, Anastasios Stathis, MD, Elizabeth H. Cull, MD, Mehdi Hamadani, MD, Alexander I. Spira, PhD MD FACP, Jay Feingold, MD PhD, David Ungar, MD, Shui He, PhD, Yajuan Qin, John Radford
Journal: Blood
Blood (2019) 134 (Supplement_1): 757.
https://doi.org/10.1182/blood-2019-128401
Published: 2019
Journal Articles

Safety and Efficacy of Adct-402 (Loncastuximab Tesirine), a Novel Antibody Drug Conjugate, in Relapsed/Refractory Follicular Lymphoma and Mantle Cell Lymphoma: Interim Results from the Phase 1 First-in-Human Study

Paolo Caimi, MD, Brad S. Kahl, MD, Mehdi Hamadani, MD, Carmelo Carlo-Stella, MD, Shui He, PhD, David Ungar, MD, Jay Feingold, MD PhD, Kirit M. Ardeshna, MA MD FRCP FRCPath, John Radford, MD FRCP, Melhem Solh, MD, Leonard Heffner, MD, Owen A. O'Connor, MD, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2874.
https://doi.org/10.1182/blood-2018-99-118133
Published: 2018
Journal Articles

Interim Results from the First-in-Human Clinical Trial of Adct-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate, in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

John Radford, MD FRCP, Brad S. Kahl, MD, Mehdi Hamadani, MD, Carmelo Carlo-Stella, MD, Paolo Caimi, MD, Kirit M. Ardeshna, MBBChir, Jay Feingold, MD PhD, Shui He, PhD, Erin Reid, MD, Melhem Solh, MD, Ki-Young Chung, MD, Leonard Heffner, MD, David Ungar, MD, Owen A. O'Connor, MD, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 398.
https://doi.org/10.1182/blood-2018-99-116081
Published: 2018
Journal Articles

Interim Data from a Phase 1 Study Evaluating Pyrrolobenzodiazepine-Based Antibody Drug Conjugate ADCT-402 (Loncastuximab Tesirine) Targeting CD19 for Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

Nitin Jain, MD, Rebecca B. Klisovic, MD, Wendy Stock, MD, David Ungar, MD, Amer M. Zeidan, MD, Ehab Atallah, MD, James McCloskey, MD, Leonard Heffner, MD, Benjamin Tomlinson, MD, Hagop M. Kantarjian, MD, Shui He, PhD, Joseph Boni, PhD, Matthew J. Wieduwilt
Journal: Blood
Blood (2017) 130 (Supplement 1): 1321.
https://doi.org/10.1182/blood.V130.Suppl_1.1321.1321
Published: 2017
Journal Articles

Results from an Ongoing Phase 1 Study Indicate ACDT-301 (Camidanlumab Tesirine) Is Well-Tolerated in Patients with Relapsed or Refractory CD25-Positive Acute Leukemia

Aaron D Goldberg, MD, Martin S. Tallman, MD, Melhem M Solh, MD, David Ungar, MD, David A. Rizzieri, MD, Roland B. Walter, MD PhD, Alexander I Spira, MD, Ki-Young Chung, MD, Wendy Stock, MD, Shui He, PhD, Joseph Boni, PhD, Ehab Atallah, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2662.
https://doi.org/10.1182/blood.V130.Suppl_1.2662.2662
Published: 2017
Journal Articles

Methodological Considerations In The Assessment Of Comorbidities Among Patients With Hemophilia Using Retrospective Claims Data

Anissa Cyaniuk, MS, David L. Cooper, MD, MBA, Desiree Hall, MS, David Ungar, MD, Chioma Smith, MPH, Tami Wisniewski, MPH
Journal: Blood
Blood (2013) 122 (21): 2947.
https://doi.org/10.1182/blood.V122.21.2947.2947
Published: 2013
Journal Articles

Chronic Hepatitis C Virus Infections in Leukemia Survivors: Prevalence, Viral Load, and Severity of Liver Disease

Ian M. Paul, Jeffrey Sanders, Francesca Ruggiero, Thomas Andrews, David Ungar, M. Elaine Eyster
Journal: Blood
Blood (1999) 93 (11): 3672–3677.
https://doi.org/10.1182/blood.V93.11.3672
Published: 1999